AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 519265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy (streptokinase)
Number of subjects: 315
Study 519265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrinolytic therapy)
Number of subjects: 315
Study 31187186 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated activated charcoal hemoperfusion (CAC-HP) for 4 hours followed by a 1-hour redistribution phase
Number of subjects: 14
Study 31187186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CAC-HP)
Number of subjects: 14
Study 25993298 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise (IC-Ex) for 12 months
Number of subjects: 31
Study 25993298 — intervention group
Group type: COMPARATOR
Intervention: Usual care (IC-Con)
Number of subjects: 31
Study 25993298 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 31
Study 23676183 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP inhibitor
Number of subjects: 25
Study 23676183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21428792 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation from a clinician to get mammography
Number of subjects: 504
Study 21428792 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation from a clinician to get Pap smears
Number of subjects: 504
Study 21428792 — intervention group
Group type: EXPERIMENTAL
Intervention: Current health insurance and a visit with healthcare provider in the past year
Number of subjects: 504
Study 19396791 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg intracameral bevacizumab (Group 1)
Number of subjects: 19
Study 19396791 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg intracameral bevacizumab (Group 2)
Number of subjects: 19
Study 16525571 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 30
Study 16525571 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide plus unfractionated heparin
Number of subjects: 30
Study 10867972 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 30
Study 10867972 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 30
Study 8778949 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Behçet's disease patients
Number of subjects: 63
Study 8778949 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive Behçet's disease patients
Number of subjects: 63
Study 8778949 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 63
Study 8778949 — intervention group
Group type: EXPERIMENTAL
Intervention: Behçet's disease patients (active and inactive)
Number of subjects: 63
Study 1764349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (needles inserted into Hegu plus Shousanli, Hegu plus Waiguan, or Shousanli positions)
Number of subjects: 0
Study 1764349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile skin stimulation (applied to the ulnar side of the palm)
Number of subjects: 0
Study 1764349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile skin stimulation (applied to the dorsal surface of the hand or forearm)
Number of subjects: 0
Study 1764349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and tactile stimulation
Number of subjects: 0
Study 1764349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile skin stimulation
Number of subjects: 0
Study 6363670 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin, ampicillin, and clindamycin (GAC)
Number of subjects: 64
Study 6363670 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin, ampicillin, and placebo (GAP)
Number of subjects: 64
Study 31215174 — intervention group
Group type: EXPERIMENTAL
Intervention: PA+C group (MoVo-work program including a PA component and a coaching component)
Number of subjects: 213
Study 31215174 — intervention group
Group type: COMPARATOR
Intervention: PA group (only the PA component)
Number of subjects: 213
Study 31215174 — intervention group
Group type: EXPERIMENTAL
Intervention: PA+C group
Number of subjects: 213
Study 31215174 — intervention group
Group type: COMPARATOR
Intervention: PA group
Number of subjects: 213
Study 30146709 — intervention group
Group type: EXPERIMENTAL
Intervention: BTL UNISON device treatments (4 sessions)
Number of subjects: 46
Study 30146709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatments)
Number of subjects: 46
Study 27315134 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800mg
Number of subjects: 0
Study 27315134 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1600mg
Number of subjects: 0
Study 27315134 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 2000mg
Number of subjects: 0
Study 27315134 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 2400mg
Number of subjects: 0
Study 27315134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (ALP) 1.5mg
Number of subjects: 0
Study 27315134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (ALP) 3.0mg
Number of subjects: 0
Study 27315134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 27315134 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) (all doses)
Number of subjects: 0
Study 27315134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (ALP)
Number of subjects: 0
Study 24951108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-delivered lifestyle modification intervention
Number of subjects: 24
Study 24951108 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based interventions, communication in the participant's chosen language(s), continuity in dietitians
Number of subjects: 24
Study 24951108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and exercise recommendations
Number of subjects: 24
Study 23306858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic loading at 45° to the long axis of the teeth of 127.4 N at a 6 Hz frequency
Number of subjects: 44
Study 23306858 — intervention group
Group type: COMPARATOR
Intervention: No cyclic loading (Control)
Number of subjects: 44
Study 19853399 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of disease-specific education delivered by a certified COPD educator
Number of subjects: 93
Study 19853399 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study 17984433 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.86% glucose, low pH/high GDP dialysis solution (pH 5.5)
Number of subjects: 10
Study 17984433 — intervention group
Group type: COMPARATOR
Intervention: 3.86% glucose, normal pH/low GDP dialysis solution (pH 7.4)
Number of subjects: 10
Study 15711977 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) ventilation
Number of subjects: 10
Study 15711977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BIPAP) ventilation
Number of subjects: 10
Study 12413989 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 73
Study 12413989 — intervention group
Group type: COMPARATOR
Intervention: Standard IVF (0.2 x 10(6)/mL)
Number of subjects: 73
Study 12413989 — intervention group
Group type: COMPARATOR
Intervention: HIC IVF (0.8 x 10(6)/mL)
Number of subjects: 73
Study 10446037 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of alpha-tocopherol
Number of subjects: 39
Study 10446037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7796786 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day zinc gluconate for 3 months
Number of subjects: 22
Study 7796786 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 22
Study 31918557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-mesh and Lichtenstein repair (M group)
Number of subjects: 97
Study 31918557 — intervention group
Group type: COMPARATOR
Intervention: Modified Kugel repair (K group)
Number of subjects: 97
Study 31918557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 30430745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) using either two bottles of sodium phosphate or 2-L polyethylene glycol
Number of subjects: 122
Study 30430745 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (no-MBP)
Number of subjects: 122
Study 30430745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 122
Study 28561902 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid BDM (ready-to-dilute solution, 50 mL admixture, infusion time 10 minutes)
Number of subjects: 0
Study 28561902 — intervention group
Group type: COMPARATOR
Intervention: Original BDM (lyophilized product requiring reconstitution, 500 mL admixture, infusion time 30 or 60 minutes)
Number of subjects: 0
Study 28561902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BDM formulations
Number of subjects: 0
Study 25132206 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 35
Study 24621834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levosimendan for 24 hours
Number of subjects: 700
Study 24621834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 24621834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levosimendan
Number of subjects: 700
Study 21656668 — intervention group
Group type: EXPERIMENTAL
Intervention: high in iTFA (10.2 g/2500 kcal)
Number of subjects: 38
Study 21656668 — intervention group
Group type: EXPERIMENTAL
Intervention: high in rTFA (10.2 g/2500 kcal)
Number of subjects: 38
Study 21656668 — intervention group
Group type: COMPARATOR
Intervention: control diet low in TFA (2.2 g/2500 kcal)
Number of subjects: 38
Study 19653484 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbol elevation (0.040 to 0.080 mm)
Number of subjects: 0
Study 19653484 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough features
Number of subjects: 0
Study 19653484 — intervention group
Group type: COMPARATOR
Intervention: Existing tactile maps (generally 0.5 mm or higher)
Number of subjects: 0
Study 17591024 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine (100 mg daily)
Number of subjects: 139
Study 17591024 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 139
Study 15527191 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11254839 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric impedance monitoring
Number of subjects: 16
Study 9532988 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg controlled‐release aspirin
Number of subjects: 3647
Study 9532988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3647
Study 8023080 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace visits by labour inspectors (LIs)
Number of subjects: 195
Study 8023080 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspection notices (INs) issued to employers
Number of subjects: 195
Study 8023080 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visits by LIs)
Number of subjects: 195
Study 2916435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 60
Study 2916435 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 60
Study 2916435 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 791536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 15
Study 791536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31895308 — intervention group
Group type: EXPERIMENTAL
Intervention: VHA and non‐VHA hospitals
Number of subjects: 365942
Study 31895308 — intervention group
Group type: COMPARATOR
Intervention: Low-performing hospitals
Number of subjects: 365942
Study 31390451 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional 3 x 3 plain retainer (0.8‐mm orthodontic wire, bonded to the canines only)
Number of subjects: 15
Study 31390451 — intervention group
Group type: COMPARATOR
Intervention: Braided retainer (0.2 x 0.7‐mm stainless steel wire, bonded to all anterior teeth)
Number of subjects: 15
Study 28342988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) received culinary-based workshops, monthly newsletters, and telephone calls incorporating Motivational Interviewing.
Number of subjects: 153
Study 28342988 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received monthly nutritional brochures from the American Institute for Cancer Research.
Number of subjects: 153
Study 26056183 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel with bevacizumab (90 mg/m2)
Number of subjects: 799
Study 26056183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (150 mg/m2)
Number of subjects: 799
Study 26056183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone (16 mg/m2)
Number of subjects: 799
Study 23470570 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed group (n=14)
Number of subjects: 42
Study 23470570 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion group (n=15)
Number of subjects: 42
Study 23470570 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed and motion group (n=13)
Number of subjects: 42
Study 23470570 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 42
Study 21749214 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for Alzheimer's disease risk assessment
Number of subjects: 276
Study 18246327 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine augmentation (25 to 400 mg/day)
Number of subjects: 50
Study 18246327 — intervention group
Group type: COMPARATOR
Intervention: Placebo augmentation
Number of subjects: 50
Study 16524854 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Wellness Program (multimodal intervention)
Number of subjects: 90
Study 16524854 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal activities)
Number of subjects: 90
Study 12967072 — intervention group
Group type: EXPERIMENTAL
Intervention: P60/EBS‐Multi
Number of subjects: 30
Study 12967072 — intervention group
Group type: EXPERIMENTAL
Intervention: P60/One‐Step
Number of subjects: 30
Study 12967072 — intervention group
Group type: EXPERIMENTAL
Intervention: P60/Prompt
Number of subjects: 30
Study 12967072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertac/EBS‐Multi
Number of subjects: 30
Study 12967072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertac/One‐Step
Number of subjects: 30
Study 12967072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertac/Prompt
Number of subjects: 30
Study 12967072 — intervention group
Group type: COMPARATOR
Intervention: P60/control
Number of subjects: 30
Study 12967072 — intervention group
Group type: COMPARATOR
Intervention: Pertac/control
Number of subjects: 30
Study 10713750 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis (HN019) supplemented milk
Number of subjects: 25
Study 10713750 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (milk alone)
Number of subjects: 25
Study 9379382 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 91
Study 9379382 — intervention group
Group type: COMPARATOR
Intervention: PMMA IOL
Number of subjects: 91
Study 1544128 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially prepared kits, accessed a total of 69 times.
Number of subjects: 26
Study 1544128 — intervention group
Group type: COMPARATOR
Intervention: Nursing protocol developed by RNs, accessed a total of 102 times.
Number of subjects: 26
Study 3936343 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial hospital setting
Number of subjects: 0
Study 3936343 — intervention group
Group type: COMPARATOR
Intervention: Inpatient setting
Number of subjects: 0
Study 3936343 — intervention group
Group type: COMPARATOR
Intervention: Cost of treatment
Number of subjects: 0
Study 31235239 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC Concussion Awareness video
Number of subjects: 140
Study 31235239 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC Concussion Fact Sheet for Parents
Number of subjects: 140
Study 29107589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metamizole ± opioids (n = 23)
Number of subjects: 43
Study 29107589 — intervention group
Group type: COMPARATOR
Intervention: Opioids alone (control group, n = 20)
Number of subjects: 43
Study 27129479 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-motivated alcohol use
Number of subjects: 3957
Study 27129479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk subtype of coping-motivated drinking
Number of subjects: 3957
Study 27129479 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking profiles based on socio-economic background
Number of subjects: 3957
Study 24739073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 24004
Study 24739073 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24004
Study 24739073 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 24004
Study 23006444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (conversion group)
Number of subjects: 15
Study 23006444 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (control group)
Number of subjects: 15
Study 20569973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (providers could view updated ICS adherence information)
Number of subjects: 2698
Study 20569973 — intervention group
Group type: COMPARATOR
Intervention: Control arm (providers could not view adherence information)
Number of subjects: 2698
Study 20569973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (providers did not view adherence information)
Number of subjects: 2698
Study 17991194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy
Number of subjects: 0
Study 17991194 — intervention group
Group type: COMPARATOR
Intervention: Total cholesterol levels
Number of subjects: 0
Study 15064002 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic doses of MPH (methylphenidate) and amphetamines
Number of subjects: 0
Study 15064002 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (stimulants)
Number of subjects: 0
Study 15064002 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulants
Number of subjects: 0
Study 11152799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheath group (sheath introduced immediately after puncture)
Number of subjects: 842
Study 11152799 — intervention group
Group type: COMPARATOR
Intervention: Control group (diagnostic catheter introduced without sheath)
Number of subjects: 842
Study 11152799 — intervention group
Group type: COMPARATOR
Intervention: Control group (crossover due to bleeding)
Number of subjects: 842
Study 11152799 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 842
Study 11152799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheath group
Number of subjects: 842
Study 10838323 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic norgestimate/EE-containing oral contraceptive (ORTHO TRI‐CYCLEN(R))
Number of subjects: 452
Study 10838323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 7936332 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg/day (Group A)
Number of subjects: 32
Study 7936332 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/day and hypocaloric diet (Group B)
Number of subjects: 32
Study 2678584 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PAI‐1 levels above 550 ng/ml
Number of subjects: 52
Study 2678584 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PAI‐1 levels below 550 ng/ml
Number of subjects: 52
Study 2678584 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients dying within a week after onset of shock (not having a rapidly fatal underlying disease)
Number of subjects: 52
Study 2678584 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 1093648 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 26
Study 1093648 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole (SMX)
Number of subjects: 26
Study 31519285 — intervention group
Group type: EXPERIMENTAL
Intervention: Grounded flaxseed (GF; 30 g/day)
Number of subjects: 90
Study 31519285 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FO; 10 g/day)
Number of subjects: 90
Study 31519285 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 29678137 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physical therapy program for knee osteoarthritis (Group PT)
Number of subjects: 0
Study 29678137 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted early mobility for hospitalized older veterans (STRIDE)
Number of subjects: 0
Study 29678137 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of helping invested family members improve veteran experiences study (iHI‐FIVES)
Number of subjects: 0
Study 29678137 — intervention group
Group type: COMPARATOR
Intervention: Complexity science‐based implementation intervention to promote team readiness (CONNECT)
Number of subjects: 0
Study 26304854 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy with S-1 plus cisplatin (CRSC)
Number of subjects: 72
Study 26304854 — intervention group
Group type: COMPARATOR
Intervention: Concurrent radiotherapy with cisplatin alone (CRC)
Number of subjects: 72
Study 26304854 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CRSC and CRC)
Number of subjects: 72
Study 25079864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 0
Study 25079864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22532102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer plus computer-tailored step advice intervention (n = 45)
Number of subjects: 92
Study 22532102 — intervention group
Group type: COMPARATOR
Intervention: Standard condition (pedometer-only intervention, n = 47)
Number of subjects: 92
Study 20601207 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 400 mcg
Number of subjects: 85